Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Ixazomib Rollover Study
NCT02924272 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
Conditions Studied
Interventions
- DRUG Ixazomib
Study Locations (20)
Other
- UZ Leuven — Leuven
- 1st Affiliated Hospital of Zhejiang University — Hangzhou
- Shanghai Chang Zheng Hospital — Shanghai
- University of Athens Medical School - Regional General Hospital Alexandra — Athens
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi — Lodz
- Centrum Onkologii Ziemi Lubelskiej — Lublin
- MTZ Clinical Research Sp z o o — Warsaw
- National University Hospital — Singapore
Ontario
- Princess Margaret Cancer Centre — Toronto
- University Health Network — Toronto
Beijing Municipality
- Peking University Third Hospital — Beijing
- Peking Union Medical College Hospital — Beijing
Tokyo
- Tokyo Metropolitan Komagome Hospital — Bunkyo-Ku
- Japanese Red Cross Medical Center — Shibuya-Ku
Georgia
- Emory University — Atlanta
Kentucky
- Appalachian Regional Healthcare — Hazard
Massachusetts
- Dana Farber Cancer Institute — Boston
Missouri
- Washington University School of Medicine — St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2024-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02924272
The ClinicalTrials.gov registry entry for NCT02924272 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 387 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention — of which Ixazomib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02924272 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Other, Ontario, Beijing Municipality. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02924272 about?
NCT02924272 is a clinical study titled "Ixazomib Rollover Study". The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
What is the current status of trial NCT02924272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2016-12-16. Estimated completion is 2024-07-03.
What conditions does trial NCT02924272 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Amyloidosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02924272?
The interventions under investigation include: Ixazomib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02924272?
This trial is sponsored by Takeda, which has 387 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02924272 being conducted?
This trial has 20 study locations across Georgia, Kentucky, Massachusetts, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.